Latest News

(UroToday.com) Haematuria is among the most common presentations from primary care to the urology clinic. The underlying rate of malignancy varies according to the severity of haematuria and tumor site. There is significant variation in the evaluation of patients with haematuria between countries, particularly with respect to imaging of the upper tract. In a moderated poster […]

(UroToday.com) Enhanced Recovery After Surgery (ERAS) is a perioperative approach to managing surgical patients. The goal of an ERAS approach is to return the patient to normal physiology more quickly. Anticipated benefits of such an approach in the radical cystectomy population include an earlier return of bowel function, decrease hospital length of stay, and decreased readmissions. […]

(UroToday.com) For the past three decades or more, transrectal ultrasound (TRUS) guided biopsy has been considered the standard diagnostic approach for the detection of prostate cancer. In the past few years, driven in large part by concerns regarding post-biopsy sepsis in patients undergoing TRUS procedures, transperineal biopsy has been increasingly utilized with equivalent cancer detection […]

(UroToday.com) Prior randomized controlled trials have demonstrated that the use of blue light cystoscopy (BLC) is associated with improved detection of both carcinoma-in-situ and papillary bladder tumors. As a result, BLC is recommended for use in patients with a history of non-muscle-invasive bladder cancer (NMIBC) undergoing surveillance or treatment cystoscopy. However, BLC is associated with a […]

(UroToday.com) As part of the American Urological Association 2020 Virtual Annual Meeting’s AUA guidelines update, Steven Kaplan, MD, from Mount Sinai Medical Center provided updates to the benign prostatic hyperplasia (BPH) guidelines from the surgical side of treatment. The purpose of this guideline is to provide an evidence-based, multidisciplinary useful reference for clinicians that emphasizes shared decision […]

(UroToday.com) Historically, it has been felt that there is a relative paucity of important germline mutations in patients with prostate cancer. However, recent work has identified important rates of mutations, particularly in DNA damage repair (DDR) pathways. The initial work in this space focused on men with advanced disease. However, more recent work has looked at […]

(UroToday.com) The utilization of multiparametric MRI before a prostate biopsy has improved risk stratification of prostate cancer. In the PROMIS study,1 a unique insight was given into the types of prostate cancer that are not detected by multiparametric MRI. 

(UroToday.com) It has previously been demonstrated that objective surgeon performance metrics using a novel recorder can directly capture surgeon manipulations on the da Vinci Surgical System.1 Subsequently, Hung et al.2 showed that using machine learning automated performance metrics (kinematic and events data) during robot-assisted radical prostatectomy can predict continence recovery, albeit at a single institution. At […]

(UroToday.com) For the past three decades or more, transrectal ultrasound-guided biopsy has been considered the standard diagnostic approach for the detection of prostate cancer. In the past few years, driven in large part by concerns regarding post-biopsy sepsis in patients undergoing TRUS procedures, transperineal biopsy has been increasingly utilized with equivalent cancer detection rate compared […]

(UroToday.com) Guideline-recommended management of high-risk prostate cancer is radical prostatectomy with pelvic lymph node dissection or radiation therapy with/without systemic therapy. Increasingly, patients with regional (N1) and distant (M1) metastases are being considered for definitive local therapy. However, the oncological value of local treatment in high-risk and metastatic prostate cancer remains controversial. At the AUA […]